Immune cells engineered to hunt brain tumors enter first human test
NCT ID NCT03389230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new immune cell therapy for people with recurrent or treatment-resistant malignant glioma, a type of brain cancer. The treatment uses the patient's own T cells, modified in the lab to recognize and attack cancer cells. The main goal is to find the safest dose and understand side effects in 29 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?